The 2021 NINDS clinical criteria for traumatic encephalopathy syndrome (TES) identified chronic traumatic encephalopathy (CTE) pathology reasonably well in older brain donors and poorly in younger ones, according to a clinicopathological study of 193 donors drawn from six brain banks. In the version of the analysis published as a conference abstract in Alzheimer's & Dementia on 24 December 2025, Jesse Mez and colleagues report sensitivity of 0.79 and specificity of 0.84 overall, 0.93 and 0.90 at age 50 and over, and 0.42 and 0.66 below age 50, where the positive likelihood ratio was 1.22 and the negative likelihood ratio 0.89, values close to no diagnostic information at all. A fuller manuscript of the same study posted to medRxiv on 2 June 2026, which states it has not been certified by peer review, reports overall figures of 0.77 (95% CI 0.64 to 0.89) and 0.84 (0.78 to 0.90), and 0.90 and 0.90 at age 50 and over.
Donors were sampled from six brain banks with different recruitment criteria, at least 15 per bank, across nine repetitive head impact or traumatic brain injury groups (from college and professional American football to military combat and to no head impact exposure at all) and five age bands from 20 to 34 up to 80 and older. Neuropathologists applied the NINDS/NIBIB neuropathological criteria blinded to clinical information; clinicians interviewed informants and reviewed records blinded to the pathology, and a panel adjudicated. Of 193 donors (79.3 per cent men, mean age 66.4 years), 57 (29.5 per cent) met clinical criteria for possible or probable CTE and 42 (21.8 per cent) had stage II to IV CTE at autopsy. All 13 false positives under age 50 also carried a mental health, substance use and/or pain diagnosis; the 11 false positives at 50 and over had non-CTE neurodegenerative and vascular pathology. Seven of the 10 false negatives were under 50.
The criteria at issue were published in Neurology in 2021 by Katz and colleagues as research criteria, with the panel itself saying validation in living populations was needed. A separate and peer-reviewed test of them appeared in Nature Medicine on 14 May 2026: John Arena and colleagues at the University of Pennsylvania reviewed antemortem records for 1,038 cases in a neurodegenerative brain bank and found 25 (2.4 per cent) met TES criteria, of whom six had CTE neuropathologic change, a positive predictive value of 24.0 per cent (95% CI 9.4 to 45.1). CTE change was present in seven of the remaining 1,013 cases (0.69 per cent), and the authors report the criteria's accuracy was driven by head impact exposure rather than by the clinical features. "It is far more likely that someone who meets the current clinical criteria does not have CTE", Arena said in a statement issued with the paper.
The brain bank authors address that result directly in their preprint, noting that predictive value depends on how common the disease is in the sample and that CTE prevalence in the Pennsylvania bank was 1.3 per cent. Both groups agree on the operational point that matters for families and for trial designers: these criteria are how people are enrolled into CTE research, and their performance is not uniform across ages. Neither study followed living patients.